

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/583,926
<b>Filing Date</b>	December 23, 2004
<b>First Named Inventor</b>	Sek Chung Fung et al.
<b>Art Unit</b>	1643
<b>Examiner Name</b>	Yaen, Christopher H.
<b>Attorney Docket No.</b>	12279-200-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	10/583,927	12/23/04	Fung et al.	
	A02	12/240,604	12/29/2008	Fung et al.	
	A03	5,011,778	4/30/1991	Newman et al.	
	A04	5,359,037	10/25/1994	Wallach et al.	
	A05	5,596,072	1/21/1997	Culpepper et al.	
	A06	5,677,165	10/14/1997	De Boer et al.	
	A07	5,705,154	1/06/1998	Dalie et al.	
	A08	5,710,023	1/20/1998	Collins et al.	
	A09	5,717,072	2/10/1998	Mosley et al.	
	A10	5,747,037	5/05/1998	Noelle et al.	
	A11	5,783,181	7/21/1998	Browne et al.	
	A12	6,156,321 B1	12/05/2000	Thorpe et al.	
	A13	6,468,528 B1	10/22/2002	Mak et al.	
	A14	6,911,530 B1	6/28/2005	Willson et al.	
	A15	7,078,494	7/18/2006	Collins et al.	
	A16	7,078,496 B1	7/18/2006	Collins et al.	
	A17	7,312,024 B2	12/25/2007	Mak et al.	
	A18	2003/0049257 A1	03/13/2003	Mak et al.	
	A19	2005/0277126 A1	12/15/2005	Collins et al.	
	A20	2008/0008648 A1	1/10/2008	Fung et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	EP 1 270 595 A1	1/02/2003	Kyowa Hakko Kogyo Co., Ltd.		
	B02	EP 1 327 681 A1	7/16/2003	Chugai Seiyaku Kabushiki Kaisha		
	B03	EP 1 646 656 A2	1/27/2005	Cambridge Antibody Technology Limited		X
	B04	WO 00/15663	3/23/2000	Cancer Research Campaign Technology Limited		

NYI-4183277v3

**EXAMINER SIGNATURE** /Christopher Yaen/ (10/11/2009)

**DATE CONSIDERED** 10/11/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y./ (10/11/2009)

# **LIST OF REFERENCES CITED BY APPLICANT** (Use several sheets if necessary)

<b>Application Number</b>	10/583.926
<b>Filing Date</b>	December 23, 2004
<b>First Named Inventor</b>	Sek Chung Fung et al.
<b>Art Unit</b>	1643
<b>Examiner Name</b>	Yaen, Christopher H.
<b>Attorney Docket No.</b>	12279-200-999

## **FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B05	WO 00/36103	6/22/2000	Genetics Institute, Inc. and John Hopkins University		
	B06	WO 02/055100	7/18/2002	Genetics Institute, LLC and the Government of the United States as Represented by the Secretary of the Department of Health and Human Services		
	B07	WO 03/018635 A1	3/06/2003	Kyowa Hakko Kogyo Co., Ltd		
	B08	WO 2005/062967 A2	7/14/2005	Tanox, Inc.		
	B09	WO 2005/062972 A2	7/14/2005	Tanox, Inc.		
	B10	WO 2008/140455 A1	11/20/2008	Tanox, Inc.		
	B11	WO 89/04838	6/01/1989	Immunex Corporation		
	B12	WO 91/09059	6/27/1991	Schering Corporation		
	B13	WO 93/15766	8/19/1993	Seragen, Inc.		
	B14	WO 94/04680	3/03/1994	Schering Corporation		
	B15	WO 94/14975	7/07/1994	Schering Corporation		
	B16	WO 95/14780	6/01/1995	Schering Corporation		
	B17	WO 97/15663	5/01/1997	Amrad Operations Pty. Ltd.		
	B18	WO 97/29131	8/14/1997	Basf Ak-Tiengesellschaft		
	B19	WO 97/31946	9/04/1997	Genetics Institute, Inc.		
	B20	WO 97/47742	12/18/1997	Smithkline Beecham Corporation and Human Genome Sciences, Inc.		
	B21	WO 98/10638	3/19/1998	Amrad Operations Pty. Ltd.		
	B22	WO 98/30240	7/16/1998	Biogen, Inc.		
	B23	WO 2005/007699 A2	01/27/2005	Cambridge Antibody Technology Limited		

## **NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	C01	ANDREWS et al., 2002, "Kinetic analysis of the interleukin-13 receptor complex," J. Biol. Chem., Vol. 277(48):46073-46078	
	C02	BELLIANTI, 1998, "Cytokines and allergic diseases: Clinical aspects," Allergy and Asthma, Proc., Vol. 19(6):337-340	

NYI-418327v3

**EXAMINER SIGNATURE** /Christopher Yaen/ (10/11/2009)

**DATE CONSIDERED** 10/11/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y./ (10/11/2009)

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Application Number	10/583,926
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung et al.
Art Unit	1643
Examiner Name	Yuen, Christopher H.
Attorney Docket No.	12279-200-999

## NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C03	BLANCHARD et al., 2005, "Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)," Clin. Exp. Allergy, Vol. 35:1096-1103	
	C04	BOST et al., 1996, "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice," Immunology, Vol. 87(4):633-641	
	C05	BREE et al., 2007, "IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys," J. Allergy Clin. Immunol., Vol. 119(5):1251-1257	
	C06	BRINKMANN et al., 1995, "TCR-stimulated naive human CD4 <sup>+</sup> 45RO <sup>+</sup> T cells develop into effector cells that secrete IL-13, IL-5, and IFN- $\gamma$ , but no IL-4, and help efficient IgE production by B cells," J. Immunol., Vol. 154(7):3078-3087	
	C07	CAMPBELL et al., 2003, "Allergic humans are hypo-responsive to CXCR3 chemokines in a Th1 immunity-promoting loop," FASEB J., Vol. 18(2):329-331	
	C08	CAPUT et al., 1996, "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor $\alpha$ chain," J. Biol. Chem., Vol. 271(28):16921-16926	
	C09	CARBALLIDO et al., 1995, "IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice," J. Immunol., Vol. 155(9):4162-4170	
	C10	CASOLARO et al., 1996, "Biology and genetics of atopic disease," Curr. Opin. Immunol., Vol. 8:796-803	
	C11	De VRIES et al., 1996, "Modulation of the human IgE response," Eur. Respir. J., Suppl. 22:58s-62s	
	C12	DE VRIES, 1994, "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," J. Invest. Dermatol., Vol. 102:141-144	
	C13	DEBINSKI et al., 1995, "A novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4," J. of Biological Chemistry, Vol. 270(28):16775-16780	
	C14	DEBINSKI et al., 1995, "Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin," Clinical Cancer Research, Vol. 1:1253-1258	
	C15	DONALDSON et al., 1998, "The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1," J. Immunol., Vol. 161:2317-2324	
	C16	DOUCET et al., 1998, "Interleukin (IL) 4 and IL-13 act on human lung fibroblasts," J. Clin. Invest., Vol. 101:2129-2139	
	C17	ENOMOTO et al., 2002, "High-throughput miniaturized immunoassay for human interleukin-13 secreted from NK3.3 cells using homogenous time-resolved fluorescence," J. of Pharm and Biomedical Analysis, Vol. 28:73-79	
	C18	FICHTNER-FEIGL et al., 2005, "IL-13 signaling through the IL-13 $\alpha_2$ receptor is involved in induction of TGF- $\beta_1$ production and fibrosis," Nature Medicine, Vol. 12: 99-106	
	C19	GABRIELSSON et al., 1998, "Increased frequencies of allergen-induced interleukin-13 producing cells in atopic individuals during the pollen season," Scand. J. Immunol., Vol. 48:429-435	
	C20	GHAFFAR et al., 1997, "IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: Comparison with IL-4 expression and modulation by topical glucocorticoid therapy," Am. J. Respir. Cell Mol. Biol., Vol. 17:17-24	
	C21	GHAMDI et al., 1997, "IL-4 and IL-3 expression in chronic sinusitis: Relationship with cellular infiltrate and effect of topical corticosteroid treatment," J. of Otolaryngology, Vol. 26(3): 160-166	
	C22	GRUNIG et al., 1998, "Requirement for IL-13 independently of IL-4 in experimental asthma," Science, Vol. 282:2261-2263	
	C23	HAMID et al., 1996, "In vivo expression of IL-12 and IL-13 in atopic dermatitis," J. Allergy Clin. Immunol., Vol. 98:225-231	
	C24	HUANG et al., 1995, "IL-13 expression at the sites of allergen challenge in patients with asthma," J. Immunol., Vol. 155:2688-2694	

NY1-4183277v3

EXAMINER  
SIGNATURE

/Christopher Yuen/ (10/11/2009)

DATE CONSIDERED

10/11/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y./ (10/11/2009)

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/583,926
<b>Filing Date</b>	December 23, 2004
<b>First Named Inventor</b>	Sek Chung Fung et al.
<b>Art Unit</b>	1643
<b>Examiner Name</b>	Yuen, Christopher H.
<b>Attorney Docket No.</b>	12279-200-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C25	HUMBERT et al., 1997, "Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma," J. Allergy Clin. Immunol., Vol. 99:657-665	
	C26	KAPP et al., 1999, "Interleukin 13 is secreted by and stimulated the growth of Hodgkin and Reed-Sternberg Cells," J. Exp. Med., Vol. 189(12):1939-1945	
	C27	KASAIAN et al., 2007, "Efficacy of IL-13 neutralization in a sheep model of experimental asthma," Am. J. Respir. Cell Mol. Biol., Vol. 36:368-376	
	C28	KAWAKAMI et al., 2001, "Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer," Cancer Research, Vol. 61:6194-6200	
	C29	KIMATA et al., 1995, "Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephritic syndrome," Eur. J. Immunol., Vol. 25:1497-1501	
	C30	KOTSIMBOS et al., 1996, "Interleukin-13 and interleukin-4 are coexpressed in atopic asthma," Proceedings of the Assoc. of American Physicians, Vol. 108(5):368-373	
	C31	KROEGER et al., 1996, "Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts," Eur. Respir. J., Vol. 9:899-904	
	C32	LEVY et al., 1997, "Role of IL-13 in CD4 T cell-dependent IgE production in atopy," Int. Arch. Allergy Immunol., Vol. 112:49-58	
	C33	MAINI et al., 1997, "Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of pseudomonas exotoxin," J. Urology, Vol. 158:948-953	
	C34	MARSH et al., 1994, "Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations," Science, Vol. 264:1152-1156	
	C35	McKENZIE et al., 1993, "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function," Proc. Natl. Acad. Sci. U.S.A., Vol. 90(8):3735-3739	
	C36	McKENZIE et al., 1994, "Measurement of interleukin-13," Current Protocols in Immunology, Unit 6.18, Suppl. 10:6.18.1-6.18.5, Coligan et al. eds., John Wiley & Sons, New York	
	C37	McKENZIE et al., 1998, "Impaired development of Th2 cells in IL-13 deficient mice," Immunity, Vol. 9:423-432	
	C38	MENTINK-KANE et al., 2004, "Opposing roles for IL-13 and IL-13 receptor $\alpha 2$ in health and disease," Immunological Reviews, Vol. 202:191-202	
	C39	NASEER et al., 1997, "Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy," Am. J. Respir. Crit. Care Med., Vol. 155:845-851	
	C40	OHNO et al., 1985, "Antigen-binding specificities of antibodies are primarily determined by seven residues of VH," Proc. Natl. Acad. Sci. U.S.A., Vol. 82(9):2945-2949	
	C41	OSHIMA et al., 2001, "Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13," J. Biol. Chem., Vol. 276(18):15185-15191	
	C42	PAWANKAR et al., 1997, "Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc $\epsilon$ RI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells," J. Clin. Invest., Vol. 99(7):1492-1499	
	C43	POSTMA et al., 1995, "Genetic susceptibility to asthma - Bronchial hyperresponsiveness coinherit with a major gene for atopy," N. Engl. J. Med., Vol. 333(14):894-900	
	C44	PUNNONEN et al., "Cytokines and IgE regulation," Allergy and Allergic Diseases: The New Mechanisms and Therapeutics, pp. 13-40. Edited by J.A. Denburg, Human Press Inc., Totowa, NJ 1998	
	C45	ROITT et al., 1996, Immunology, Fourth Edition, Published by Mosby, London, pp. 22-1-22.5 and glossary	
	C46	ROITT, L.M., 1988, Essential Immunology, Sixth Edition, Blackwell Scientific Publications, Oxford, pp. 195-196	
	C47	SCHILDBACH et al., 1993, "Modulation of antibody affinity by a non-contact residue," Protein Sci. Vol. 2(2):206-214	

NYI-418327v3

**EXAMINER SIGNATURE** /Christopher Yaen/ (10/11/2009)

**DATE CONSIDERED**

10/11/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y./ (10/11/2009)

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/583,926
<b>Filing Date</b>	December 23, 2004
<b>First Named Inventor</b>	Sek Chung Fung et al.
<b>Art Unit</b>	1643
<b>Examiner Name</b>	Yuen, Christopher H.
<b>Attorney Docket No.</b>	12279-200-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C48	SKINNIDER et al., 2002, "Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma," Blood, Vol. 99(2):618-626	
	C49	SKINNIDER et al., 2002, "The role of interleukin 13 in classical Hodgkin lymphoma," Leuk. Lymphoma, Vol. 43(6):1203-1210	
	C50	TEKKANAT et al., 2001, "IL-13-induced airway hyperactivity during respiratory syncytial virus infection is STAT6 dependent," J. Immunol., Vol. 166:3542-3548	
	C51	TERABE et al., 2000, "NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway," Nat. Immunol., Vol. 1(6):515-520	
	C52	TERABE et al., 2004, "Role of IL-13 in regulation of anti-tumor immunity and tumor growth," Cancer Immunol. Immunother., Vol. 53:79-85	
	C53	TRIEU et al., "Inhibition of Hodgkin lymphoma cell line growth using an adenovirus expressing the soluble IL-13 decoy receptor (sIL-13Ralpha2)," Blood vol. 100(11):Abstract no. 2272 & 44 Annual meeting of the American Society of Hematology, Philadelphia, PA, USA, December 6-10, 2002	
	C54	TRIEU et al., 2004, "Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo," Cancer Research, Vol. 64:3271-3275	
	C55	VAN DER POUW KRAAN et al., 1998, "The role of IL-13 in IgE synthesis by allergic asthma patients," Clin. Exp. Immunol., Vol. 111:129-135	
	C56	VAN DER POUW KRAAN et al., 1996, "Human IL-13 production is negatively influenced by CD3 engagement - enhancement of IL-13 production by cyclosporine A," J. Immunol., Vol. 156(5):1818-1823	
	C57	VUGMEYSTER et al., 2008, "Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms," Intl. Immunopharmacol., Vol. 8:477-483	
	C58	WARNER, 1998, "Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma," Pediatr. Allergy Immunol., Vol. 9:56-60	
	C59	WILLIS-KARP et al., 1998, "Interleukin-13: central mediator of allergic asthma," Science, Vol. 282:2258-2261	
	C60	WYNN, T. A., 2003, "IL-13 effector functions," Annual Review of Immunol., Vol. 21:425-456	
	C61	YANG et al., 2004, "Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling," Cytokine, Vol. 28:224-232	
	C62	YANG et al., 2005, "Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice," J. Pharmacol. Exp. Ther., Vol. 312:8-15	
	C63	YSEL et al., 1998, "The role of IgE in asthma," Clin. Exp. Allergy, Vol. 28, Supp. 5:104-109	
	C64	ZHANG et al., 2003, "Identification of monoclonal antibodies against IL-6," Molecular Cardiology of China, Vol. 3(3):152-156	
	C65	ROITT et al., Immunology, 2000, Publisher "Mir", Moscow, pages 110-111.	

NYI-4183277v3

**EXAMINER SIGNATURE** /Christopher Yuen/ (10/11/2009)

**DATE CONSIDERED** 10/11/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y./ (10/11/2009)